Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents
Authors' conclusion
Most antihypertensive class medications were not associated with statistically significant weight gain when prescribed to adolescents.
Study context
- Population
- Adolescents aged 13.0–19.5 years with ≥ 1 antihypertensive class medication order during 2010–2019, regardless of indication; 13% with hypertension diagnosis at baseline
- Participants
- 23,853 adolescents
- Exposure
- Common antihypertensive class medications and BMI z-score change
- Clonidinen = 7,491
- Guanfacinen = 6,411
- Lisinopriln = 3,584
- Propranololn = 3,015
- Spironolactonen = 1,926
- Atenololn = 1,426
- Outcome
- Estimated population-level BMI z-score change
- Follow-up
- 12 months after medication initiation
Methodological detailsmulti-site US research network, electronic health record data, inverse probability weighting with marginal structural models
- Multi-site US research network
- Electronic health record data
- Inverse probability weighting with marginal structural models
Main finding
As reported in the abstract
Propranolol
0.19
95% CI 0.09–0.29
Lisinopril
−0.06
95% CI −0.10–-0.01
Observational data: associations, not effects.
Original publication
Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents. Pediatr Obes. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →